Our next-generation viral immunotherapies pack a powerful trio of attributes – selective attack, potent destruction, and broad immune stimulation – to enable the potential to transform outcomes for patients.
| Investment Date | Original Shares | Original Value | Current Shares | Current Value | % Return | Split Adjustment | Current Price |
|---|---|---|---|---|---|---|---|
| October 2, 2020 | 1,000.00 | $16,000.00 | 1,000.00 | $176.00 | -98.9% | 1 | $0.18 |
Return calculations do not include reinvested cash dividends.
Data Provided by Refinitiv. Minimum 15 minutes delayed.
